Create account

Coverage dated September 30, 2026

Moderna Shares Slump As Citi Downgrades To 'Sell’ After Cancer Vaccine Rally

Headline from Forbes

Moderna stock has rallied more than 200% since August, following positive Phase 3 trial results for a melanoma vaccine.

Forbes's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.

Read the reports

Reports & sources

3 articles, oldest first.

  1. Forbes

    Moderna Shares Slump As Citi Downgrades To 'Sell’ After Cancer Vaccine Rally (opens Forbes)

    Published

    Forbes's feed description

    Moderna stock has rallied more than 200% since August, following positive Phase 3 trial results for a melanoma vaccine.

  2. Investor's Business Daily

    After Moderna's Dizzying Rally, It's Time To Sell, Says Analyst (opens Investor's Business Daily)

    Published

    Investor's Business Daily's feed description

    After nearly quadrupling over the past month, it's time to get out of Moderna stock, a Citi analyst said Wednesday as he downgraded shares.

  3. Bloomberg

    Moderna Tumbles as Citi Advises Selling Following 600% Rally (opens Bloomberg)

    Published

    Bloomberg's feed description

    Moderna Inc. shares fell the most in a month on Wednesday as a Citigroup Inc. analyst recommended selling the stock, saying its current valuation is “unjustifiable” following an outsized rally.